NURLF (Neural Therapeutics) Accounts Payable & Accrued Expense: $0.13 Mil (As of Jan. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Neural Therapeutics Accounts Payable & Accrued Expense?

Neural Therapeutics NURLF Accounts Payable & Accrued Expense is $0.13 Mil as of Jan. 2026. The stock has 1 warning sign investors should review.

Neural Therapeutics's quarterly accounts payable & accrued expense declined from Jul. 2025 ($0.13 Mil) to Oct. 2025 ($0.12 Mil) but then increased from Oct. 2025 ($0.12 Mil) to Jan. 2026 ($0.13 Mil).

Neural Therapeutics's annual accounts payable & accrued expense declined from Jul. 2023 ($0.36 Mil) to Jul. 2024 ($0.22 Mil) and declined from Jul. 2024 ($0.22 Mil) to Jul. 2025 ($0.13 Mil).

Neural Therapeutics Accounts Payable & Accrued Expense Historical Data

* Premium members only.

The historical data trend for Neural Therapeutics's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neural Therapeutics Accounts Payable & Accrued Expense Chart

Neural Therapeutics Annual Data
Trend Jul20 Jul21 Jul22 Jul23 Jul24 Jul25
Accounts Payable & Accrued Expense
Get a 7-Day Free Trial 0.22 0.36 0.36 0.22 0.13

Neural Therapeutics Quarterly Data
Jul20 Jul21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
Accounts Payable & Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.19 0.12 0.13 0.12 0.13

Neural Therapeutics Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

What does a Accounts Payable & Accrued Expense of $0.13 Mil mean?
Neural Therapeutics (NURLF) has a Accounts Payable & Accrued Expense of $0.13 Mil as of Jan. 2026. Accounts payable and accrued expenses are amounts a company expects to pay to suppliers and others. View historical data on Neural Therapeutics and its competitors.
Is Neural Therapeutics' Accounts Payable & Accrued Expense too high?
Neural Therapeutics' current Accounts Payable & Accrued Expense is $0.13 Mil.
How does Neural Therapeutics' Accounts Payable & Accrued Expense compare to VRTX and REGN?
Neural Therapeutics' Accounts Payable & Accrued Expense of $0.13 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable & Accrued Expense for a Biotechnology company?
A good Accounts Payable & Accrued Expense depends on the Biotechnology industry context. However, Accounts Payable & Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable & Accrued Expense mean?
A high Accounts Payable & Accrued Expense can signal that a stock is expensive relative to its fundamentals. Accounts payable and accrued expenses are amounts a company expects to pay to suppliers and others. View historical data on Neural Therapeutics and its competitors. Neural Therapeutics's current Accounts Payable & Accrued Expense is $0.13 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neural Therapeutics stock overvalued right now?
Neural Therapeutics (NURLF) has a current Accounts Payable & Accrued Expense of $0.13 Mil. The current Accounts Payable & Accrued Expense is $0.13 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable & Accrued Expense calculated?
Accounts Payable & Accrued Expense is calculated from a company's financial statements. For Neural Therapeutics (NURLF), the current Accounts Payable & Accrued Expense is $0.13 Mil as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Neural Therapeutics Business Description

Other Exchanges M6B:GermanyNURL:Canada
Address 1-130 Adelaide Street West, Suite 3002, Toronto, ON, CAN, M5H 3P5
Neural Therapeutics Inc is a wholly-owned subsidiary of High Fusion focused on ethnobotanical drug discovery and development company. Neural Therapeutics is focused on developing products and conducting research on the psychoactive cacti plants with the primary objective to find where the historical use in traditional medicine proves to be effective and capitalizing on the opportunities that can be applied in modern medical and natural health products markets.